

British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA Study)

Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.

Over 30,000 patients registered in the study since 2001.

NOW ACCEPTING NEW REGISTRATIONS AND FOLLOW-UP DATA ONLINE VIA THE NEW WEB PORTAL!

To sign up please visit <https://bsrbr.org/database/>

Eligibility for registration



Diagnosis of Rheumatoid Arthritis



Aged 16 Years or over

Starting eligible biologic treatment



ANTI-TNF

HUMIRA
(adalimumab originator)*

ENBREL
(etanercept originator)*

REMICADE
(infliximab originator)*

*patients must be biologic, biosimilar & targeted therapy naive to be eligible

BIOSIMILARS

HULIO (adalimumab)	ERELZI (etanercept)
AMGEVITA (adalimumab)	BENEPALI (etanercept)
HYRIMOZ (adalimumab)	INFLECTRA (infliximab)
IMRALDI (adalimumab)	REMSIMA IV (infliximab)
RIXATHON (rituximab)	REMSIMA SC (infliximab)
IDACIO (adalimumab)	FLIXABI (infliximab)

OTHER TARGETED THERAPIES

OLUMIANT
(baracitinib)

CIMZIA
(certolizumab)

ROACTEMRA
(tocilizumab)

KEVZARA
(sarilumab)

XELJANZ
(tofacitinib)

RINVOQ
(upadacitinib)

Registration within 6 months of the therapy start date*



*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Please contact the BSRBR-RA team with any questions

0161 275 1652 / 7390 biologics.register@manchester.ac.uk